A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer

1. Wiechno, P.
2. Somer, B.G.
3. Mellado, B.
4. Chłosta, P.L.
5. Cervera Grau, J.M.
6. Castellano, D.
7. Reuter, C.
8. Stöckle, M.
9. Kamradt, J.
10. Pikiel, J.
11. Durán, I.
12. Wedel, S.
13. Callies, S.
14. André, V.
15. Hurt, K.
16. Brown, J.
17. Lahn, M.
18. Heinrich, B.